Fig. 1.
Pooled exposure–response analyses of patients with locally advanced or metastatic NSCLC or UC. The proportions of responders are plotted vs (a) AUC or (b) Cmin at cycle 1. In part (a), for legibility, 1 extreme AUC value (> 15,000 μg.day/mL) is not displayed on the plot. Wald P values from logistic regression of the proportion of responders vs exposure are displayed. Gray solid lines and shaded areas represent the logistic regression slope model and 95% PI. Filled circles and error bars represent the proportions of responders in exposure quartiles and 95% CI; vertical lines are the limits of the exposure quartiles. Cross markings (×) represent response events (0: no, 1: yes). Triangle and two-headed arrows represent the mean exposure and exposure interval between the 10th and 90th percentiles, respectively, for patients receiving atezolizumab 1200 mg q3w. Cycle 1 AUC corresponds to the AUC during the first 3 weeks after treatment start and with PK parameters estimated based on cycle 1 data only. AUC area under the concentration–time curve, Cmin minimum (trough) serum atezolizumab concentration, CR complete response, n number of patients, NSCLC non-small cell lung cancer, PI prediction interval, PK pharmacokinetics, PR partial response, UC urothelial carcinoma